Market Insight

AI became a major theme this week, alongside advances in regenerative medicine and connected care, as MedTech companies raised capital to accelerate commercialization and expand clinical impact.
TYBR Health raises $30M Series A to expand orthopedic hydrogel platform
TYBR Health has raised $30M in a Se

TYBR Health has raised $30 million in a Series A financing round led by Vensana Capital and Mutual Capital Partners to expand commercialization of its B3 GEL hydrogel platform for orthopedic surgery.
The funding will support broader market access, new clinical studies, and expanded indications for B3

CARPL.ai has raised $10 million in a Series A funding round led by the International Finance Corporation (IFC), with participation from Stellaris Venture Partners and other investors, to expand its radiology AI marketplace and enterprise platform.
The company’s vendor-neutral platform gives healthcar

Spryte Medical has completed enrollment in the INSYTE Trial, a key clinical study evaluating its investigational nOCT™ Imaging System for use during endovascular treatment of intracranial aneurysms.
The FDA-approved IDE study enrolled 65 patients across 8 centers in 3 countries and is designed to ass

Traferox Technologies has received FDA Premarket Approval (PMA) for its TorEx® Lung Perfusion System, an ex vivo lung perfusion (EVLP) platform designed to assess donor lungs outside the body before transplantation.
The system enables transplant teams to evaluate the function of donor lungs initially

Cardinal Health has acquired urology-focused medical supplier Strive Medical and AdaptHealth’s diabetes business in a combined $360 million deal aimed at strengthening its at-home care solutions platform.
The acquisitions expand Cardinal’s capabilities across diabetes management and urology, building

Endo Tools Therapeutics (ETT) has raised €20 million ($23 million) in an oversubscribed Series C financing round to accelerate commercialization of its endomina® platform and recently FDA-cleared endomina® EZFuse system.
The round was led by Capricorn Partners through its Capricorn Healthtech Fund II

Ability Neurotech has completed the first-in-human procedure for its implantable brain-computer interface (BCI), marking the company's entry into clinical-stage development.
The procedure was performed at the Technical University of Munich (TUM) University Hospital Rechts der Isar as part of a study

Bluejay Diagnostics has completed patient enrollment in its pivotal SYMON-II multicenter clinical validation study, reaching its target of 750 patients ahead of schedule.
The prospective study is evaluating the company's investigational Symphony™ IL-6 rapid diagnostic test, which is designed to help